Colvin-Adams Monica, Taylor Anne L
Cardiac Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Cleve Clin J Med. 2007 Mar;74(3):227-34. doi: 10.3949/ccjm.74.3.227.
The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057). This placebo-controlled trial was the first to evaluate a therapy in a specific racial group, and it points the way to a more individualized approach to heart failure therapy.
非裔美国人心力衰竭试验（A-HeFT）发现，对于患有晚期心力衰竭的非裔美国患者，如果在其治疗方案中添加固定剂量的硝酸异山梨酯和肼屈嗪联合用药，他们的病情会有所改善，而他们中的大多数人原本的治疗方案中已经包含了一种血管紧张素转换酶（ACE）抑制剂或血管紧张素受体阻滞剂（ARB）、一种β受体阻滞剂和一种利尿剂（《新英格兰医学杂志》2004年；351:2049 - 2057）。这项安慰剂对照试验首次在特定种族群体中评估一种治疗方法，并为心力衰竭治疗更个体化的方法指明了方向。
